BioTime's Clinical Grade Stem Cells From Subsidiary ES Cell International to Be Used in Planned CIRM-Funded Preclinical Studies of Huntington's Disease
April 27, 2015 at 09:05 AM EDT
BioTime, Inc. (NYSE MKT: BTX) today announced that the clinical-grade human Embryonic Stem (hES) cell lines from BioTime's wholly-owned ...